AU2002220571A1 - (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use - Google Patents

(2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use

Info

Publication number
AU2002220571A1
AU2002220571A1 AU2002220571A AU2057102A AU2002220571A1 AU 2002220571 A1 AU2002220571 A1 AU 2002220571A1 AU 2002220571 A AU2002220571 A AU 2002220571A AU 2057102 A AU2057102 A AU 2057102A AU 2002220571 A1 AU2002220571 A1 AU 2002220571A1
Authority
AU
Australia
Prior art keywords
ylmethoxycarbonylamino
tetrahydropyrimidin
adamantan
ylcarbamoyl
benzoylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220571A
Inventor
Gerhard Breipohl
Thomas R. Gadek
Jean-Francois Gourvest
Robert Mcdowell
Anuschirwan Peyman
Jean-Marie Ruxer
Theodor Wollmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Genentech Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH, Genentech Inc filed Critical Aventis Pharma Deutschland GmbH
Publication of AU2002220571A1 publication Critical patent/AU2002220571A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002220571A 2000-10-10 2001-09-27 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use Abandoned AU2002220571A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00121986A EP1197488A1 (en) 2000-10-10 2000-10-10 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
EP00121986 2000-10-10
PCT/EP2001/011186 WO2002030910A1 (en) 2000-10-10 2001-09-27 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use

Publications (1)

Publication Number Publication Date
AU2002220571A1 true AU2002220571A1 (en) 2002-04-22

Family

ID=8170045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220571A Abandoned AU2002220571A1 (en) 2000-10-10 2001-09-27 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use

Country Status (8)

Country Link
US (1) US6867213B2 (en)
EP (2) EP1197488A1 (en)
JP (1) JP2004511472A (en)
AR (1) AR030874A1 (en)
AT (1) ATE466844T1 (en)
AU (1) AU2002220571A1 (en)
DE (1) DE60142063D1 (en)
WO (1) WO2002030910A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327527D0 (en) * 2003-11-26 2003-12-31 Univ Bern Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists

Also Published As

Publication number Publication date
JP2004511472A (en) 2004-04-15
EP1326847B1 (en) 2010-05-05
EP1197488A1 (en) 2002-04-17
WO2002030910A1 (en) 2002-04-18
DE60142063D1 (en) 2010-06-17
ATE466844T1 (en) 2010-05-15
EP1326847A1 (en) 2003-07-16
US6867213B2 (en) 2005-03-15
AR030874A1 (en) 2003-09-03
US20040039006A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU2003252299A1 (en) Novel physiologically active substance
AU2001281954A1 (en) Heterocyclic substituted herbicidal sulphonic acid anilides
HUP0402616A3 (en) Biphenylmethyl-thiazolidinedones, biphenyl-propionic acid derivatives, their use as ppar-gamma activators and pharmaceutical and cosmetic compositions containing them
AU3501400A (en) Hair care compositions comprising amino acid compounds
AU2002340470A1 (en) L-dopa ethyl ester salts and uses thereof
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
AU2001286242A1 (en) Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
AU2001232238A1 (en) Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
HUP0203226A3 (en) Pharmaceutical composition comprising benzamide derivative as active ingredient
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
AU4562000A (en) 4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU2002220571A1 (en) (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use
AU2267897A (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
AU2002361096A1 (en) Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
NO20012673L (en) New pharmaceutical composition and process for its preparation
AU6471800A (en) 4-(substituted phenyl)-5-halopyrimidine derivatives and herbicides containing the same as the active ingredient
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU2003257407A1 (en) S-(+)-3-{1-(2-(2,3-dihydro-1h-indol-3-yl)ethyl)-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
AU2002363776A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
AU2001240702A1 (en) Derivatives of p- hydroxy phenyl propionic acid as antiproliferative agents
WO2001070205A3 (en) Composition comprising paracetamol and niflumic acid
AU2002214422A1 (en) New use of 2-(4-isobutylphenyl)propionic acid
AU2003216904A1 (en) Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate